期刊文献+

哺乳动物雷帕霉素靶蛋白在人结肠癌中的表达及其对HT-29细胞增殖凋亡的影响 被引量:4

Expression of mammalian target of rapamycin in colon cancer and its effect on proliferation and apoptosis of human colon cancer HT-29 cells
原文传递
导出
摘要 目的探讨哺乳动物雷帕霉素靶蛋白(mTOR)基因在人结肠癌组织中的表达及其对HT-29细胞增殖与凋亡的影响。方法免疫组织化学方法检测磷酸化mTOR(p-mTOR),在郑州大学第一附属医院普通外科2009年10月至2010年6月50例结肠癌组织和50例正常结肠组织中的表达情况。体外合成mTOR小干扰RNA(siRNA),转染人结肠癌HT-29细胞为实验组,同时设空白对照组(不转染)及无义对照组(转染无义siRNA),Western印迹法检测各组HT-29细胞的mTOR蛋白表达;四甲基偶氮唑蓝法检测细胞增殖;原位末端标记法检测细胞凋亡。结果结肠癌组织中p-mTOR的表达高于对照组[60%(30例)比14%(7例),P〈0.05],mTOR的表达和淋巴结转移、肿瘤的分化程度相关(r=0.311、0.427,均P〈0.05)。实验组HT-29细胞mTOR的表达和细胞增殖均低于空白对照组和无义对照组(0.39±0.25比1.18±0.05、1.46±0.09,0.275±0.033比0.460±0.028、0.450±0.037,均P〈0.05);细胞凋亡指数则均高于空白对照组和无义对照组(12.33±1.53比0.33±0.31、1.67±0.58,均P〈0.05)。结论在结肠癌组织中存在mTOR高表达,mTORsiRNA对HT-29细胞mTOR基因的表达有抑制作用,能抑制HT-29细胞的增殖并促进其凋亡。 Objective To explore the expression of mammalian target of rapamycin (roTOR) in colon cancer and the inhibitory effect of roTOR siRNA on the proliferation and apoptosis of human colon cancer HT-29 cells. Methods Immunohistochemistry was employed to detect the expression of phosphorylated mTOR (p-roTOR) in colon cancer tissues (n = 50) and normal colon tissues (n = 50) from First Affiliated Hospital of Zhengzhou University (October 2009 to June 2010 ). The correlations were examined between the expression of p-roTOR and such clinical pathological data as colon cancer staging and lymph node metastasis. The oligonucleotide templates of roTOR siRNA were designed and employed to transfect HT-29. The nonsense control groups were established accordingly by siRNA with an insignificant order. And the blank group had no transfection. The protein level of mTOR was measured by Western blotting. The method of MTF was used to detect the cell proliferation. And the method of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was employed to detect the apoptosis. Results The expression of p-roTOR was higher in the colon cancer group than the control group [ 60% (30 cases) vs 14% (7 cases), P 〈 0.05 ]. And the expression level was correlated with the degree of lymph node metastasis and tumor differentiation ( r = 0. 311, 0. 427, both P 〈 0. 05 ). The expression of roTOR protein in the transfection group was lower than the blank and the nonsense control groups (0. 39 ± 0. 25 vs 1.18 ±0.05, 1.46 ± 0.09, both P 〈 0. 05 ). The proliferation was lower than those of the blank and the nonsense control groups (0. 275 ± 0. 033 vs 0. 460 ± 0. 028, 0. 450± 0. 037, both P 〈 0. 05 ). The apoptotic indices were higher than those of the blank and control groups ( 12. 33 ±. 1.53 vs 0. 33 ± 0. 31, 1.67± 0. 58, both P 〈 0. 05 ). Conclusion The expression of mTOR was higher in colon cancer tissues than that in normal colon tissues. The RNA interference of roTOR in HT-29 cell line can effectively knock down the expression of roTOR so as to significantly inhibit cell proliferation and promote cell apoptosis.
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第41期2899-2902,共4页 National Medical Journal of China
关键词 结肠肿瘤 RNA干扰 HT29细胞 MTOR Colonic neoplasms RNA interference HT29 cells roTOR
  • 相关文献

参考文献12

  • 1Bai X, Jiang Y. Key factors in mTOR regulation. Cell Mol Life Sci, 2010,67:239-253.
  • 2Helliwell SB, Wagner P, Kunz J, et al. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell, 1994,5 : 105-118.
  • 3Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene, 2008,27 Suppl 2: S43-51.
  • 4Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oneogene, 2010, 29: 3733-3744.
  • 5Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Onco|, 2009,27 : 2278-2287.
  • 6周静,王春友,刘涛,吴河水,周峰,熊炯炘,赵刚,杨明,殷涛,周蒙滔.PI3K/mTOR信号通路参与胰腺肿瘤干细胞样SP细胞生存增殖的调控[J].中华医学杂志,2008,88(42):2994-2998. 被引量:5
  • 7Bjornsti MA, Houghton PJ. The TOR pathway:a target for cancer therapy. Nat Rev Cancer, 2004,4:335-348.
  • 8Slattery ML, Herrick J, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: roTOR, PTEN, STK1, RPKAA1, PRKAG2, TSC1, TSC2, PI3K, and Aktl. Carcinogenesis, 2010,31 : 1604-1611.
  • 9张燕捷,房静远,孙丹凤,赵树靓,沈冠凤,郑青,朱红音.雷帕霉素与PD98059联合调控人结直肠癌细胞周期和mTOR信号转导通路[J].中华肿瘤杂志,2007,29(12):889-893. 被引量:7
  • 10Pencreach E, Gu6rin E, Nicolet C, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-lalpha axis. Clin Cancer Res, 2009, 15:1297-1307.

二级参考文献43

共引文献15

同被引文献77

  • 1陈庆永,王春友,吴河水,陈道达.外源性PTEN基因诱导人乳腺癌MDA468细胞凋亡[J].中华医学杂志,2005,85(1):33-36. 被引量:12
  • 2胡新华,张强,杨军,刘程伟,张志深.反义mTOR逆转录病毒载体对血管平滑肌细胞增殖的抑制作用[J].中国普通外科杂志,2006,15(12):912-916. 被引量:4
  • 3LIU Hong,ZHANG Su-zhan,WU Yu-lian,FANG He-qing,LI Jiang-tao,SHENG Hong-wei,WANG Yong.Diagnosis and surgical treatment of pancreatic endocrine tumors in 36 patients:a single-center report[J].Chinese Medical Journal,2007(17):1487-1490. 被引量:11
  • 4Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16:2672-2685.
  • 5Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophospbamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol, 2006, 24:2019-2027.
  • 6Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol, 2008, 17:301-311.
  • 7Castaneda CA, Cortes-Funes H, Gomez HL, et al. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev, 2010, 29:751-759.
  • 8Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell, 2007, 11:498-512.
  • 9Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer, 2009, 100: 315-321.
  • 10Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92:205-216.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部